Endoscopic sleeve gastroplasty: From whence we came and where we are going
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The most effective and durable treatment for obesity is bariatric surgery. However, less than 2% of eligible patients who fulfill the criteria for bariatric surgery undergo the procedure. As a result, there is a drive to develop less invasive therapies to combat obesity. Endoscopic bariatric therapies (EBT) for weight loss are important since they are more effective than pharmacological treatments and lifestyle changes and present lower adverse event rates compared to bariatric surgery. Endoscopic sleeve gastroplasty (ESG) is a minimally invasive EBT that involves remodeling of the greater curvature. ESG demonstrated favorable outcomes in several centers, with up to 20.9% total body weight loss and 60.4% excess weight loss (EWL) on 2-year follow-up, with a low rate of severe adverse events (SAE). As such, it could be considered safe and effective in light of ASGE/ASMBS thresholds of > 25% EWL and ≤ 5% SAE, although there are no comparative trials to support this. Additionally, ESG showed improvement in diabetes mellitus type 2, hypertension, and other obesity-related comorbidities. As this procedure continues to develop there are several areas that can be addressed to improve outcomes, including device improvements, technique standardization, patient selection, personalized medicine, combination therapies, and training standardization. In this editorial we discuss the origins of the ESG, current data, and future developments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Perioperative safety in the longitudinal assessment of bariatric surgery
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901836 · Cited by 1,392
Sharaiha, R. Z., Kumta, N. A., Saumoy, M., Desai, A. P., Sarkisian, A. M., Benevenuto, A., Tyberg, A., Kumar, R., Igel, L., Verna, E. C., et al. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.12.012 · Cited by 268
The Action for Health in Diabetes (Look AHEAD) Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0509 · Cited by 125
ENDOSCOPIC SLEEVE GASTROPLASTY FOR OBESITY TREATMENT: TWO YEARS OF EXPERIENCE
LOPEZ-NAVA, G., GALVÃO, M. P., BAUTISTA-CASTAÑO, I., FERNANDEZ-CORBELLE, J. P., TRELL, M., & LOPEZ, N. (2017) · ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/0102-6720201700010006 · Cited by 83
Cited by
Nunes, B. C. M., de Moura, D. T. H., Kum, A. S. T., de Oliveira, G. H. P., Hirsch, B. S., Ribeiro, I. B., Gomes, I. L. C., de Oliveira, C. P. M., Mahmood, S., Bernardo, W. M., et al. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06747-4 · Cited by 41
Effect of Aspiration Therapy on Obesity-Related Comorbidities: Systematic Review and Meta-Analysis
Jirapinyo, P., de Moura, D. T. H., Horton, L. C., & Thompson, C. C. (2020) · Clinical Endoscopy · doi:10.5946/ce.2019.181 · Cited by 32
“Additionally, for some patients with class I and II obesity who do not meet the criteria for surgery and those with class III obesity who do not want to undergo surgery, EBMTs may represent a feasible option for the treatment of obesity and potentially other metabolic comorbidities.(1-6) Aspiration therapy (AT) is one…”
BackgroundSelf-citationUpdates in endoscopic bariatric and metabolic therapies.
Qureshi, H., Saeed, N., & Jovani, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031126 · Cited by 21
“This is thought to increase satiety and delay gastric emptying [21,22].”
Background
Metadata
- Authors
- Moura, D. T. H. D., Moura, E. G. H. D., & Thompson, C. C.
- Venue
- World Journal of Gastrointestinal Endoscopy
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2019-05-16
- Volume
- 11
- Issue
- 5
- Pages
- 322-328
- ISSN
- 1948-5190 (ISSN-L)
- OpenAlex
- W2946695610
- Cited by
- 39
- References
- 5
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.